555
Find out about Activated P13K Delta Syndrome
Click Here

Management and treatment of APDS vary from patient to patient, even within
affected families, and depends on the symptoms present and disease severity.¹

Symptom Management ²

 

Antibiotics and Antivirals:

Antibiotics and antivirals are often given to treat or prevent recurrent infections.

 

Immunoglobulin Replacement Therapy:

Majority of APDS patients have antibody deficiencies and reeive immunoglobulin replacement therapy (IRT) given subcutaneously or intravenously.

 

Immuno-suppressive Treatments:

Rituximab is one of many immuno-suppresive treatments used for autoimmune complications.

Current Treatments Under Investigation ²

 

Stem Cell Transplantation:

For the most severe patients with life threatening complications hematopoietic stem cell transplantation (HSCT) has been used to correct the underlying dysfunction though with a high benefit risk consideration.

 

PI3K-delta Inhibitors:

Selective PI3K-delta inhibitors are currently being studied in clinical trials and have the potential in the future to offer a targeted treatment option for APDS patients.

 

Leniosilib (CDZ173):

Leniosilib (CDZ173) an investigational drug not yet approved by the US Food and Drug Administration (FDA), is an oral selective PI3K-delta inhibitor currently under investigation for the treatment of APDS.

Find out more about the APDS Clinical Program

References:

 1. Condliffe AM, Chandra A. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome. Front Immunol. 2018;9:338. Published 2018 Mar 5. doi:10.3389/fimmu.2018.00338

2. Coulter TI, Cant AJ. The Treatment of Activated PI3Kδ Syndrome. Front Immunol. 2018;9:2043. Published 2018 Sep 7. doi:10.3389/fimmu.2018.02043